141 related articles for article (PubMed ID: 36387181)
1.
Zeng Z; Wang T; He J; Wang Y
Front Oncol; 2022; 12():1010084. PubMed ID: 36387181
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
[TBL] [Abstract][Full Text] [Related]
3. Detection of an EML4-ALK fusion mutation secondary to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer: a case report.
Ren KH; Qin WW; Wang Y; Peng JC; Hu WX
Ann Palliat Med; 2022 Jul; 11(7):2503-2509. PubMed ID: 35927783
[TBL] [Abstract][Full Text] [Related]
4. Successful management of a lung cancer patient harbouring both
Fujita K; Naka M; Ito T; Kanai O; Maekawa K; Nakatani K; Mio T
Respir Med Case Rep; 2021; 33():101393. PubMed ID: 33854939
[TBL] [Abstract][Full Text] [Related]
5. Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy.
Zhai X; Wu Q; Pu D; Yin L; Wang W; Zhu D; Xu F
Front Oncol; 2021; 11():782682. PubMed ID: 35070986
[TBL] [Abstract][Full Text] [Related]
6. Frequency, clinical features and differential response to therapy of concurrent
Liu J; Mu Z; Liu L; Li K; Jiang R; Chen P; Zhou Q; Jin M; Ma Y; Xie Y; Xiang J; Li B; Ma Y; Mao X; Zhang L; Zhang T; Wu D
Drug Des Devel Ther; 2019; 13():1809-1817. PubMed ID: 31213769
[No Abstract] [Full Text] [Related]
7. Effectiveness of alectinib and osimertinib in a brain metastasized lung adenocarcinoma patient with concurrent EGFR mutations and DCTN1-ALK fusion.
Yin Q; Guo T; Zhou Y; Sun L; Meng M; Ma L; Wang X
Thorac Cancer; 2022 Feb; 13(4):637-642. PubMed ID: 34964276
[TBL] [Abstract][Full Text] [Related]
8. Response to erlotinib in a patient with lung adenocarcinoma harbouring the
Alì G; Chella A; Lupi C; Proietti A; Niccoli C; Boldrini L; Davini F; Mussi A; Fontanini G
Oncol Lett; 2015 Apr; 9(4):1537-1540. PubMed ID: 25788996
[TBL] [Abstract][Full Text] [Related]
9. Potential Therapeutic Strategy for
Huang MH; Lee JH; Hung PS; Chih-Hsin Yang J
JTO Clin Res Rep; 2022 Nov; 3(11):100405. PubMed ID: 36325153
[TBL] [Abstract][Full Text] [Related]
10. Primary resistance to crizotinib treatment in a non-small cell lung cancer patient with an EML4-ALK rearrangement: a case report.
Zhang L; Li Y; Zhang S; Gao C; Nie K; Ji Y
Cancer Biol Med; 2018 May; 15(2):178-181. PubMed ID: 29951342
[TBL] [Abstract][Full Text] [Related]
11. Coexistence of a novel SETD2-ALK, EML4-ALK double-fusion in an advanced lung adenocarcinoma patient after alectinib resistant and response to immunotherapy combined with chemotherapy: a case report.
Zhu L; Qin J
Discov Oncol; 2023 Apr; 14(1):44. PubMed ID: 37055606
[TBL] [Abstract][Full Text] [Related]
12.
von Buttlar X; Reuss JE; Liu SV; Kim C
JTO Clin Res Rep; 2021 Jun; 2(6):100179. PubMed ID: 34590027
[TBL] [Abstract][Full Text] [Related]
13. A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene.
Tanaka H; Hayashi A; Morimoto T; Taima K; Tanaka Y; Shimada M; Kurose A; Takanashi S; Okumura K
BMC Cancer; 2012 Nov; 12():558. PubMed ID: 23181703
[TBL] [Abstract][Full Text] [Related]
14. Responses to crizotinib and chemotherapy in patients with lung adenocarcinoma harboring a concomitant
Li Y; Su S; Cai G; Lin Q; Zhou Y; Ouyang J; Chen B; Ye J; Wu X; Chen C
Mol Clin Oncol; 2017 Aug; 7(2):173-182. PubMed ID: 28781781
[TBL] [Abstract][Full Text] [Related]
15. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
16. Coexistence of a novel NBEA-ALK, EML4-ALK double-fusion in a lung adenocarcinoma patient and response to alectinib: A case report.
Liang Q; Xu H; Liu Y; Zhang W; Sun C; Hu M; Zhu Y; Tan S; Xu X; Wang S; Liu L
Lung Cancer; 2021 Dec; 162():86-89. PubMed ID: 34763158
[TBL] [Abstract][Full Text] [Related]
17. Lung adenocarcinoma with EGFR 19Del and an ALK rearrangement benefits from alectinib instead of an EGFR-TKI: A case report.
Wang H; Zhu S; Li Z; Qi X; Zhang L; Ke L; Lin Y
Medicine (Baltimore); 2022 Sep; 101(35):e30316. PubMed ID: 36107507
[TBL] [Abstract][Full Text] [Related]
18. Activity of EGFR-tyrosine kinase and ALK inhibitors for EML4-ALK-rearranged non-small-cell lung cancer harbored coexisting EGFR mutation.
Miyanaga A; Shimizu K; Noro R; Seike M; Kitamura K; Kosaihira S; Minegishi Y; Shukuya T; Yoshimura A; Kawamoto M; Tsuchiya S; Hagiwara K; Soda M; Takeuchi K; Yamamoto N; Mano H; Ishikawa Y; Gemma A
BMC Cancer; 2013 May; 13():262. PubMed ID: 23714228
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib Overcomes Alectinib Resistance Caused by Amphiregulin in a Leptomeningeal Carcinomatosis Model of ALK-Rearranged Lung Cancer.
Arai S; Takeuchi S; Fukuda K; Taniguchi H; Nishiyama A; Tanimoto A; Satouchi M; Yamashita K; Ohtsubo K; Nanjo S; Kumagai T; Katayama R; Nishio M; Zheng MM; Wu YL; Nishihara H; Yamamoto T; Nakada M; Yano S
J Thorac Oncol; 2020 May; 15(5):752-765. PubMed ID: 31972351
[TBL] [Abstract][Full Text] [Related]
20. Genetic and treatment profiles of patients with concurrent Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) mutations.
Yang X; Zhong J; Yu Z; Zhuo M; Zhang M; Chen R; Xia X; Zhao J
BMC Cancer; 2021 Oct; 21(1):1107. PubMed ID: 34654390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]